SBIR-STTR Award

Development of an AMF Orion/Blackrock HD-USEA based 60/128 channel implantable wireless simulator system for human auditory nerve implants
Award last edited on: 5/21/2023

Sponsored Program
SBIR
Awarding Agency
NIH : NIDCD
Total Award Amount
$1,697,894
Award Phase
2
Solicitation Topic Code
173
Principal Investigator
Sandeep Negin

Company Information

Blackrock Microsystems LLC (AKA: I2S Micro Implantable Systems LLC)

630 Komas Drive Suite 200
Salt Lake City, UT 84108
   (801) 582-5533
   sales@blackrockmicro.com
   www.blackrockmicro.com
Location: Single
Congr. District: 01
County: Salt Lake

Phase I

Contract Number: 1R44DC018757-01
Start Date: 6/1/2020    Completed: 5/31/2021
Phase I year
2020
Phase I Amount
$221,177
The development of implantable high channel electronics interfacing with the central and peripheral nervous system has been a continuing effort for decades covering a wide range of applications. Reliable and clinically proven high channel solutions with hermetic encapsulation of the electronics that would be suitable for the use in a Cochlear or auditory nerve have so far not been demonstrated. The project aims to develop and translate a novel clinical high (60-128) channel implantable programmable stimulator (IPS) for use in Cochlear (CI) and auditory nerve (ANI) implants to expand the useable parameter space (electrode count, tonal range, lower stimulation threshold) far beyond current limits. In this project we will evaluate performance, biocompatibility and safety of a new chronically implantable can and programmable stimulator with high channel feedthrough and assembly for the use in a high channel cochlear and auditory nerve implant that uses the high-density Utah Slant Electrode Array (HD-USEA). The HD-USEA is used as penetrating auditory nerve electrode in a new type of intracranial auditory prosthesis that targets the auditory nerve en route to the brainstem in order to substantially improve hearing performance over the current standard of care, the cochlear implant (CI) (NIH 1UG3NS107688-01). Clinical feasibility and value in human subjects will be demonstrated in a new high channel auditory prosthesis being developed for use in human subjects under an existing UG3/UH3 grant. The current approach is however limited in the ability to use the potentially far higher electrode channel count and subsequent tonal range and resolution due to the limited channel count (12) of the conventional (MED-EL Synchrony) CI stimulator. While this approach is a strength of the UG3/UH3 project that combines existing clinically proven products into one new system as the fastest and lowest risk path towards first in human demonstration, it falls short in using the unique capabilities of the HD- USEA architecture or other higher channel CI electrodes.

Public Health Relevance Statement:
Narrative The project aims to develop and translate a novel clinical high (60-128) channel implantable programmable stimulator (IPS) for use in Cochlear (CI) and auditory nerve (ANI) implants to expand the useable parameter space (electrode count, tonal range, lower stimulation threshold) far beyond current limits. Clinical feasibility and value in human subjects will be demonstrated in a new high channel auditory prosthesis being developed for use in human subjects under an existing UG3/UH3 grant (NIH 1UG3NS107688-01).

Project Terms:
Acoustic Nerve; Adoption; Aging; Animal Model; Architecture; Auditory Prosthesis; base; biomaterial compatibility; brain computer interface; Brain Stem; Chronic; Clinical; clinical research site; Cochlear Implants; Cochlear Nerve; Communities; Data; density; Development; Devices; Diagnostic; Electrodes; Electronics; Epilepsy; falls; first-in-human; Funding; Grant; Hearing; Human; human subject; Implant; Implanted Electrodes; improved; In Vitro; in vivo; Insurance; Lead; Life Expectancy; Mechanics; Medical Device; Metals; Modeling; neural implant; neuroregulation; nonhuman primate; novel; Ocular Prosthesis; Operative Surgical Procedures; Orphan; Performance; Peripheral; Peripheral Nerves; Peripheral Nervous System; Phase; phase 2 designs; programs; Publishing; Reproducibility; Research; Resolution; Retina; Risk; Route; Safety; standard of care; Sterilization; Study Subject; System; Technology; Testing; Time; Translating; United States National Institutes of Health; Utah; Vision; Visual Cortex; voltage; Wireless Technology

Phase II

Contract Number: 4R44DC018757-02
Start Date: 6/1/2020    Completed: 7/31/2023
Phase II year
2021
(last award dollars: 2022)
Phase II Amount
$1,476,717

The development of implantable high channel electronics interfacing with the central andperipheral nervous system has been a continuing effort for decades covering a wide range ofapplications. Reliable and clinically proven high channel solutions with hermetic encapsulation ofthe electronics that would be suitable for the use in a Cochlear or auditory nerve have so far notbeen demonstrated.The project aims to develop and translate a novel clinical high (60-128) channel implantableprogrammable stimulator (IPS) for use in Cochlear (CI) and auditory nerve (ANI) implants toexpand the useable parameter space (electrode count, tonal range, lower stimulation threshold)far beyond current limits. In this project we will evaluate performance, biocompatibility and safetyof a new chronically implantable can and programmable stimulator with high channel feedthroughand assembly for the use in a high channel cochlear and auditory nerve implant that uses thehigh-density Utah Slant Electrode Array (HD-USEA). The HD-USEA is used as penetratingauditory nerve electrode in a new type of intracranial auditory prosthesis that targets the auditorynerve en route to the brainstem in order to substantially improve hearing performance over thecurrent standard of care, the cochlear implant (CI) (NIH 1UG3NS107688-01). Clinical feasibilityand value in human subjects will be demonstrated in a new high channel auditory prosthesis beingdeveloped for use in human subjects under an existing UG3/UH3 grant. The current approach ishowever limited in the ability to use the potentially far higher electrode channel count andsubsequent tonal range and resolution due to the limited channel count (12) of the conventional(MED-EL Synchrony) CI stimulator. While this approach is a strength of the UG3/UH3 project thatcombines existing clinically proven products into one new system as the fastest and lowest riskpath towards first in human demonstration, it falls short in using the unique capabilities of the HD-USEA architecture or other higher channel CI electrodes.

Public Health Relevance Statement:
Narrative The project aims to develop and translate a novel clinical high (60-128) channel implantable programmable stimulator (IPS) for use in Cochlear (CI) and auditory nerve (ANI) implants to expand the useable parameter space (electrode count, tonal range, lower stimulation threshold) far beyond current limits. Clinical feasibility and value in human subjects will be demonstrated in a new high channel auditory prosthesis being developed for use in human subjects under an existing UG3/UH3 grant (NIH 1UG3NS107688-01).

Project Terms: